Neovascular age-related macular degeneration Trials in Bakersfield, United States
Conditions / Neovascular age-related macular degeneration / Bakersfield, United States
Neovascular age-related macular degeneration is a medical condition with active clinical research programs worldwide.
17 total trials for this combination
Showing top 10 of 17 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03683251 | Extension Study for the Port Delivery System With Ranibizumab (Portal) | RECRUITING | — |
| NCT06223958 | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06190093 | A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD) | COMPLETED | PHASE3 |
| NCT06495918 | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04757610 | OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) | TERMINATED | PHASE3 |
| NCT04853251 | A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | RECRUITING | PHASE4 |
| NCT06491914 | A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03630952 | Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) | TERMINATED | PHASE3 |
| NCT03677934 | A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration | COMPLETED | PHASE3 |
| NCT02713204 | Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection | COMPLETED | PHASE2 |